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We show that two host-encoded primary RNAs (pri-miRs) and the corresponding microRNA
(miR) clusters – widely reported to have cell transformation-associated activity – are regu-
lated by EBNA3A and EBNA3C. Utilising a variety of EBV-transformed lymphoblastoid cell
lines (LCLs) carrying knockout-, revertant- or conditional-EBV recombinants, it was possible
to demonstrate unambiguously that EBNA3A and EBNA3C are both required for transacti-
vation of the oncogenic miR-221/miR-222 cluster that is expressed at high levels in multiple
human tumours – including lymphoma/leukemia. ChIP, ChIP-seq, and chromosome confor-
mation capture analyses indicate that this activation results from direct targeting of both
EBV proteins to chromatin at the miR-221/miR-222 genomic locus and activation via a long-
range interaction between enhancer elements and the transcription start site of a long non-
coding pri-miR located 28kb upstream of the miR sequences. Reduced levels of miR-221/
miR-222 produced by inactivation or deletion of EBNA3A or EBNA3C resulted in increased
expression of the cyclin-dependent kinase inhibitor p57KIP2, a well-established target of
miR-221/miR-222. MiR blocking experiments confirmed that miR-221/miR-222 target
p57KIP2 expression in LCLs. In contrast, EBNA3A and EBNA3C are necessary to silence
the tumour suppressor cluster miR-143/miR-145, but here ChIP-seq suggests that repres-
sion is probably indirect. This miR cluster is frequently down-regulated or deleted in human
cancer, however, the targets in B cells are unknown. Together these data indicate that
EBNA3A and EBNA3C contribute to B cell transformation by inhibiting multiple tumour sup-
pressor proteins, not only by direct repression of protein-encoding genes, but also by the
manipulation of host long non-coding pri-miRs and miRs.
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Author Summary
A relatively unbiased screen of human microRNAs (miRs) revealed that in EBV-trans-
formed B cells, a miR cluster, miR-221/miR-222, that is frequently up-regulated in cancer,
is induced by the latent EBV only if the viral nuclear proteins EBNA3A and EBNA3C are
both expressed. The same two EBV proteins silence a tumour-suppressor miR cluster
miR-143/miR-145. The induction of miR-221/miR-222 results from the activation of a
long non-coding primary RNA (pri-miR) via long-range chromatin looping between
enhancer elements that bind EBNA3A and EBNA3C and the transcription start site of the
pri-miR. A well-established target of miR-221/miR-222 is the cyclin-dependent kinase
(CDK) inhibitor p57KIP2, which, because it can inactivate various CDKs, can inhibit cell
proliferation—but might have additional functions in B cells. Since EBNA3A and
EBNA3C also cooperate to repress the expression of at least two other inhibitors of CDKs
(p16INK4a and p15INK4b), this implies a degree of functional redundancy in the deregula-
tion of cell cycle checkpoints by latent EBV. This study has shown for the first time that
this capacity to reduce expression of multiple cell cycle inhibitors results not only from
direct repression of protein-encoding genes, but also the activation of a long non-coding
RNA and cluster of oncogenic miRs.
Introduction
Epstein-Barr virus (EBV) is a gamma-herpesvirus etiologically linked to several B cell malig-
nancies in humans, including Burkitt lymphoma (BL), Hodgkin lymphoma (HL) and diffuse
large B cell lymphoma (DLBCL). Primary infection with EBV is usually asymptomatic in early
childhood, but if delayed until adolescence it may manifest as a benign lymphoproliferative
syndrome known as infectious mononucleosis (IM) [1]. After primary infection the virus per-
sists in a latent state in a memory B cell population for the lifetime of infected individuals [2,3].
Approximately 90% of the adult human population is latently infected with EBV. Moreover, in
vitro, EBV has the unique capacity to infect, activate and induce the continuous proliferation
(also known as “transformation” or “immortalisation”) of quiescent B cells leading to the estab-
lishment of lymphoblastoid cell lines (LCLs) [1,4]. These cells carry the viral genome as extra-
chromosomal episomes from which only nine latency-associated proteins are expressed [the
latency III program—six nuclear proteins (EBNAs 1, 2, 3A, 3B, 3C, LP) and three membrane
proteins (LMP1, LMP2A, LMP2B)] along with several RNA species. The latter include Bam
H1 A rightward transcript (BART) RNAs that are processed to produce ~20 miRs. These
latency-associated gene products act together to activate the quiescent B cells into the cell cycle
and maintain their proliferation [1,4].
EBNA3A, EBNA3B and EBNA3C are three viral proteins encoded by genes that probably
arose from gene duplication events during the evolution of EBV since they are adjacent in the
viral genome and all have a similar gene structure—short 5’ exon and long 3’ exon [5,6]. How-
ever, despite this assumed common origin, these three proteins share only limited amino acid
sequence homology and have distinct functions. Genetic studies initially indicated EBNA3A
and EBNA3C, but not EBNA3B, are required and essential for B cell transformation [7,8]. Sub-
sequently it was shown that LCLs expressing a conditionally active form of EBNA3A or
EBNA3C proteins fail to proliferate when either EBNA3A or EBNA3C is non-functional
[9,10]. However, more recently many LCLs have been generated using recombinant EBV from
which EBNA3A has been deleted—EBNA3A-knockout (KO) viruses [11,12]. Nevertheless,
EBNA3A is still believed to play an important role in B cell transformation, since cell lines
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deficient in EBNA3A –at least in the early stages of outgrowth—tend to exhibit reduced rates
of proliferation and undergo changes in host gene expression as they become established
[11,12]. In contrast to EBNA3A and EBNA3C, not only is EBNA3B unnecessary for B cell
transformation in culture, in vivo it behaves as a tumour suppressor—apparently attenuating
the oncogenic potential of EBV [13].
The EBNA3s are well established as regulators of transcription (reviewed in [14]. It seems
that none of the EBNA3s bind directly to DNA and that they exert their effects on transcription
through association with cellular transcription factors such as RBP-JK/CBF1, PU.1, SPI1,
BATF and IRF4 [15,16,17,18,19,20,21]. EBNA3A and EBNA3C also interact with and recruit
cellular factors associated with the covalent modification of histones such as histone deacety-
lases (HDACs), histone acetyltransferases (eg p300), CtBP and components of the polycomb
group protein repressor complexes [12,22,23,24,25,26,27]. It has also recently been shown that
they can regulate gene expression through the modulation of chromatin looping between distal
regulatory elements and gene transcription start sites (TSS) [20]. Chromatin immunoprecipita-
tion coupled to high throughput DNA sequence (ChIP-seq) analyses have identified many
thousands of specific genomic loci where the EBNA3s can be detected—many of these sites
overlap for EBNA3A and EBNA3C binding [19,20,28,29]. Probably related to this co-localisa-
tion on chromatin, independent microarray and follow-up studies revealed that EBNA3A and
EBNA3C extensively cooperate in the regulation of many cellular genes [14,20,21,29]. Well
characterised target genes include those encoding important survival and cell cycle regulators
such as the pro-apoptotic, BH3-only protein BIM and the cyclin-dependent kinase inhibitors
(CDKIs) p16INK4a and p15INK4b [12,27,30,31,32]. These are repressed by the combined action
of EBNA3A and EBNA3C and this is probably necessary to enhance survival, prevent cell cycle
arrest and inhibit cell senescence early after the infection of primary B cells by EBV (reviewed
in [31]). Repression of p16INK4A expression appears to be a particularly important function of
EBNA3C early during the infection and transformation of B cells [30,31]. In addition to their
well-established role in regulating the expression of cellular protein-encoding transcripts, we
wanted to investigate whether EBNA3A and EBNA3C could also modify the expression of
non-coding RNAs, particularly miRs that could also contribute to the B cell transformation
process and EBV latency.
MiRs are a class of endogenous, short (~22 nucleotides), non-coding RNAs that play impor-
tant roles in regulating many physiological processes including apoptosis, cell proliferation, dif-
ferentiation and oncogenesis, by controlling gene expression at post-transcriptional levels.
Most mammalian miRs are initially transcribed by RNA polymerase II (Pol II) that generates
primary miRNA transcripts (pri-miRs), which are then cleaved by the nuclease, Drosha, into
~79-nt precursor miRNAs (pre-miRs) and exported into the cytoplasm. Once in the cytoplasm,
these pre-miRNAs are processed into mature miRNAs by the Dicer nuclease and incorporated
into the RNA-induced silencing complex (RISC) to target specific messenger RNAs (mRNAs)
leading to either repression of translation or degradation of mRNA or often both (reviewed in
[33,34]). Each miR species can generally target a large number of different mRNAs [35] and
more than one species of miR can target mRNA from a single gene. There is accumulating evi-
dence indicating that miRs are major regulators in the initiation and progression of human
cancer by acting as either tumor suppressor or oncogenic miRs (oncomiRs, [36,37]). Moreover,
various studies indicate that growth-transforming viruses, including EBV, can encode mimics
of, and/or modulate the expression of host cell miRs (for example [4,38,39,40,41,42]).
MiR-221 and miR-222 are highly conserved, co-expressed miRs encoded as a cluster located
on chromosome X and have been reported to be overexpressed in many types of cancer [43],
including thyroid carcinoma [44], glioblastoma [45], prostate carcinoma [46,47], bladder can-
cer [48], pancreatic cancer [49], hepatocellular carcinoma [50], acute myeloid leukemia [51]
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and diffuse large B cell lymphoma [52,53,54]. Meta-analysis performed on over 1000 assorted
human tumours, suggests that elevated expression of miR-221 and miR-222 is associated with
poor overall survival of many cancer patients [55]. This well characterised oncogenic activity is
likely to be related to the ability of miR-221/miR-222 to regulate cell cycle progression by
directly targeting mRNA corresponding to CDKIs p57KIP2 (CDKN1C) and p27KIP1 (CDKN1B)
[50,56,57,58,59].
In contrast to miR-221/miR-222, miR-143 and miR-145 are tumour suppressor miRs that
have been reported to inhibit the proliferation of many cancer-and non-cancer-derived cell
lines. It has also been suggested that they might play roles in cell senescence [60,61,62]. MiR-
143/miR-145 coding sequences are located in a cluster on chromosome 5 and are co-tran-
scribed as a single pri-miR transcript [61,63]. Their reduced expression has been observed in a
wide range of tumours, including gastric cancer [64], colorectal cancer [65], cervical cancer
[66], lung cancer [67], breast cancer [68], nasopharyngeal carcinoma [69], bladder cancer [70],
prostate cancer [71] ovarian cancer [72], hepatocellular carcinoma [73] and some B cell malig-
nancies [74]. However, although various target mRNAs have been described in these reports,
none have been particularly well characterised and to our knowledge no B cell-specific targets
have been described.
Here—following a relatively unbiased array screen for miRs regulated by EBNA3A and/or
EBNA3C in the context of latent infection with EBV—we identified the oncogenic miR-221/
miR-222 cluster as being activated and the tumor suppressor miR-143/miR-145 cluster as
being repressed by EBNA3A together with EBNA3C. Further characterisation revealed that
up-regulation of miR-221/miR-222 –resulting from the transactivation of a 28kb long non-
coding pri-miR—was associated with almost complete ablation of p57KIP2 expression in EBV-
infected B cells.
Results
Confirming leads from low-density arrays for EBNA3A and EBNA3C
regulated host miRs in LCLs
In order to determine whether EBNA3A and EBNA3C regulate host cell miR levels in the con-
text of latently infected B cells, the expression of 377 human, biologically active, mature miRs
was examined using Taqman real-time PCR low density arrays (TLDA) to analyse two LCLs
conditional for EBNA3C function (3CHT lines) cultured for 28 days with or without the acti-
vating ligand 4HT and two EBNA3A-KO LCLs and lines established with the respective rever-
tant virus (REV). Several cellular miRs appeared to be regulated by either EBNA3A or
EBNA3C or both. The total set of data acquired was screened for leads to be followed-up by
quantitative real-time PCR (qPCR) measurements, but was not subjected to statistical analysis.
Positive leads that were of particular interest—because they have been reported in the literature
to have either oncogenic activity (the miR-221/miR-222 cluster) or tumour suppressor activity
(the miR-143/miR-145 cluster)–were chosen for more detailed analysis. Both of these clusters
are well conserved in vertebrate evolution [43,75,76].
Fig 1A shows the results of qPCR assays for miR-221/miR-222 in extracts from four inde-
pendent EBNA3A-KO LCLs and four LCLs established with revertant viruses (and therefore
expressing all the latency-associated EBV proteins). Consistently, failure to express EBNA3A
resulted in a large reduction in miR-221 and miR-222 expression (Fig 1A and S1 Fig). Similarly
using two independent LCLs conditional for EBNA3C function (3CHT, established in a
p16-null B cell background in order to allow the cells to proliferate in the absence of EBNA3C,
as described in [30]), it was shown that removal of the activating ligand (4HT) resulted in a less
substantial, but clearly significant reduction in both miR-221 and miR-222 expression (Fig 1A
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and S1 Fig). Analysis of the same lines for expression of miR-143 and miR-145 confirmed the
TLDA result showing that in the absence of EBNA3A or functional EBNA3C (by washing out
4HT) there was an increase in the expression of miR-143 and miR-145 (Fig 1B). When
EBNA3A was deleted there was particularly robust expression of both miR-143 and miR-145.
When conditional EBNA3C was inactivated there was a rather modest, but still significant and
reproducible increase in both miRs. Consistent with this, when 4HT was added to a p16-null
EBNA3C-conditional LCL that had been established in its absence (never HT), there was a sub-
stantial repression of the miR-143/miR-145 cluster (Fig 2A and S1 Fig). The differential expres-
sion of miRs are not due to the 4HT treatment since no significant change in miR expression
was detected in two wild-type LCLs (D11 and D13 LCLWT) treated with 4HT for 30 days (S2
Fig). Control RNAs RNU48 and ALAS1 were unaffected by the EBNA3A or EBNA3C status of
the LCLs (S3 Fig). Expression of protein-encoding gene clusters previously reported to be regu-
lated by EBNA3A and EBNA3C (eg CXCL9/CXCL10 and ADAM28/ADAMDEC1) was as
expected from previous reports ([20,21,28], Fig 2B and S3 Fig). Although in some knockout
and revertant LCL pairs, EBNA3B expression appeared to influence the levels of these miR
clusters, the changes were very slight and/or inconsistent (S1 and S4 Figs).
Fig 1. Regulation of miR clusters by EBNA3A and EBNA3C. (A) MiR-221 and miR-222 expression in four independent LCLs EBNA3A-KO and
EBNA3A-REV (D1, D2, D3 and D4) as well as two p16-null LCL 3CHT (A2 and C1) cultured for 29 days with (+HT) or without 4HT (Washed) were
determined by real time quantitative RT-PCR (qPCR). MiR-221/miR-222 expression was normalized to RNU6B and is shown relative to each “wild type” cell
LCL EBNA3A-REV (3A-REV) or p16-null 3CHT cultured with 4HT (+HT). (B) As in (A) but analysing miR-143 and miR-145 expression.
doi:10.1371/journal.ppat.1005031.g001
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Establishment and validation of EBNA3A-ERT2 conditional LCLs
We, and others, have found that when EBNA3A-KO LCLs are produced there is a tendency for
the selection of changes in gene expression as the lines become more clonal (for example loss
of/reduced retinoblastoma (Rb) expression has been reported in independent studies [11,12]).
In order to establish that the changes in miR expression highlighted by the TLDA (and subse-
quently confirmed by qPCR) were due to direct regulation of transcription by EBNA3A –rather
than the result of selection during clone development—it was necessary to construct and vali-
date an EBV recombinant that is conditional for EBNA3A (EBNA3A-ERT2) and use this to
produce new LCLs. EBNA3A-ERT2 is very similar to the EBNA3C conditional virus used in
the initial assays (Fig 1 and [12,30]), but has a fusion of the C-terminus of EBNA3A with a
slightly more modified estrogen-receptor that responds to 4HT but not estrogen (see Material
and Methods). LCLs established with these viruses were validated for the expression of
EBNA3A and other EBV latency-associated proteins by western blotting; in the absence of
4HT the EBNA3A-ERT2 fusion protein is almost completely degraded, but the expression of
other latency-associated EBV proteins was unaltered (Fig 3).
Regulation of miR-221/miR-222 and miR-143/miR-145 in
EBNA3A-ERT2 conditional LCLs
Several EBNA3A-ERT2 LCLs produced from two different individual B cell donors (D11 for
LCLs number 1–2 and D13 for cell lines number 3–4) and a mixed donor population of B cells
(LCL number 5) were established in the presence of 4HT and then analyzed ~30 days after
removal (-4HT) or leaving in 4HT (+4HT) (Fig 4A). Consistently on removal of 4HT
(washed), miR-221 and miR-222 were expressed at a lower level (Fig 4B), whereas miR-143
and miR-145 were modestly induced (Fig 4C). As with the experiments using conditional
EBNA3C, when EBNA3A-conditional cells that had been grown into LCLs in the absence of
4HT (never HT), there was a substantial repression of miR-143 and miR-145 when 4HT was
added to the culture medium (Fig 5A and S1 Fig). All these experiments showed that—like
EBNA3C –active EBNA3A is necessary for the regulation of both miR clusters, ruling out the
Fig 2. Activation of EBNA3C repressesmiR-143/miR-145 expression. (A) MiR-143, miR-145 and RNU48 expression were analysed by qPCR from
p16-null LCL 3CHT established without the presence of 4HT (never HT) or 30 days after 4HT was added to culture medium (+HT). MiR levels in p16-null LCL
3CHT +HT are relative to the LCL never HT. (B) As in (A) but analysing the expression of ALAS1, ADAM28 and ADAMDEC1 by qPCR as controls for the
activation of EBNA3C following the addition of 4HT.
doi:10.1371/journal.ppat.1005031.g002
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possibility of clonal selection as an explanation for the changes in expression seen in the
EBNA3A-KO lines. EBNA3A-ERT2 function was further validated by qPCR for expression of
previously characterised EBNA3A target genes (CXCL9 and CXCL10 [21], Fig 5B and S5 Fig).
EBNA3A and EBNA3C up-regulate expression of pri-miR-221/222
MiR-221 and miR-222, which together form a cluster, are thought to both be processed from a
common pri-miR. Interestingly, three different species of pri-miR-221/222, approximately
2kb, 28kb and 108kb, have been described [51]. The expression of these three pri-miR-221/222
differs in different cell lines, however, publically available RNA-seq data from ENCODE
revealed that in GM12878 (an EBV-immortalised LCL) the major pri-miR-221/222 to be
expressed is the 28kb species (Fig 6A). Using LCLs described above (Figs 1 and 4) it was estab-
lished that both EBNA3A and EBNA3C are necessary to up-regulate the 28kb pri-miR-221/
222 (Fig 6B and 6C). The level of pri-miR-221/222 in those cells echoes the level of the mature
miR-221/miR-222 detected (compare Figs 1 and 4 with Fig 6). Consistent with this, when 4HT
was added to EBNA3A-ERT2 LCLs or EBNA3C-HT LCLs never HT, there was a significant
up-regulation of the pri-miR-221/222 (Fig 6D and 6E). The activation of both EBNA3A and
EBNA3C through addition of 4HT not only up-regulates the pri-miR-221/222, but also
increases the expression of the mature miR-221 and miR-222 in these cells (S6 Fig). Further-
more, it was possible to show that EBNA3A and EBNA3C repress the well-characterised pri-
miR-143/145 in the same LCLs (S7 Fig).
Fig 3. Validation of EBNA3A-ERT2 conditional LCLs. Expression of latency-associated EBV proteins
EBNA1, EBNA2, EBNA3A-ERT2, EBNA3B, EBNA3C, EBNA-LP and LMP1 were analysed byWestern
blotting extracts from four EBNA3A-ERT2 LCLs (named 1, 2, 3 and 4) cultured in medium with 4HT (+) and
29 days without 4HT (-). The blot was probed for γ-tubulin as a control for loading.
doi:10.1371/journal.ppat.1005031.g003
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ChIP-seq and ChIP-qPCR analysis of the miR-221/miR-222 and miR-
143/miR-145 loci
EBNA3A and EBNA3C are viral transcription factors that can be targeted to host genes at sites
proximal to transcription start sites (TSS) and/or distal regulatory elements and sometimes
modulate looping of chromatin between these sites to modify gene expression [19,20,21,29].
Therefore, in order to determine whether the regulation of miR-221/miR-222 and/or miR-143/
miR-145 might result from direct binding of either EBNA3A or EBNA3C –or both—to
Fig 4. Regulation of miRs in EBNA3A-conditional LCLs. (A) Five EBNA3A-ERT2 LCLs (established in the presence of 4HT and named from 1 to 5) were
cultured for ~30 days with (+) or without (-) 4HT and EBNA3A-ERT2 protein expression was analysed by western blot. (B) MiR-221/miR-222 expression was
determined by qPCR using total RNA extracted from the same five EBNA3A-ERT2 cell lines (LCLs 1, 2, 3, 4 and 5). (C) As in (B) but analysing miR-143 and
miR-145 expression.
doi:10.1371/journal.ppat.1005031.g004
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chromatin at the genomic locus of each miR cluster, genome-wide chromatin immunoprecipi-
tation (ChIP) data sets were interrogated. ChIP-seq was performed using D11 LCLs expressing
either an epitope-tagged EBNA3A (3A-TAP) or an epitope-tagged EBNA3C (3C-TAP) and
the immunoprecipitation (IP) was performed using an anti-FLAG antibody; this was followed
by high throughput DNA sequencing (S8 Fig and K. Paschos et al, manuscript in preparation;
[27]). Analysis of the genomic locus including miR-221/miR-222 (chromosome Xq11.3)
revealed a region located approximately 9kb downstream of the TSS for the 28kb pri-miR-221/
222 that includes three binding sites for EBNA3C (sites BS2a, BS2b and BS3 in Fig 7A). One of
these sites precisely overlapped an EBNA3A-binding site (BS2b) and one partially overlapped
(BS3). Sites BS2a and BS2b are spaced only 1kb apart at a location previously reported to be a
cis-acting enhancer element involved in the regulation of both miR-221 and miR-222 [47]. An
additional EBNA3C-only binding site (BS1) was located about 60kb downstream of the pri-
miR-221/222 TSS (Fig 7A). Robust binding of EBNA3C-TAP to sites BS1, BS2a, BS2b, and BS3
was confirmed by ChIP-qPCR (Fig 7B), but no binding was observed using control primers
corresponding to another region previously described as an enhancer (EnhA [47], Fig 7A)
Under similar ChIP-qPCR conditions, and again using the anti-FLAG antibody, significant
binding of EBNA3A-TAP could also be detected in BS2a, BS2b and BS3, whereas no binding
was detected for site BS1 or EnhA (Fig 7C). Taken together, these results identified an ‘intra-
genic’ region where both EBNA3A and EBNA3C bind to chromatin (BS2a, BS2b and BS3).
ENCODE data (displayed on the UCSC genome browser) shows this region has high levels of
the activation associated histone modification H3K27ac—providing further evidence that it
probably acts as an enhancer of transcription in LCLs (Fig 7A).
In contrast, interrogation of ChIP-seq data corresponding to the miR-143/miR-145 locus
(chromosome 5q.32)–over a region of more than 1Mb either side of the putative TSS of the
pri-miR-143/145 –failed to reveal any EBNA3A- or EBNA3C-binding sites (compare S9 Fig
with Fig 7A). Our interpretation of these data is that transcriptional regulation of pri-miR-143/
145 (and hence mature miR-143/miR-145) is unlikely to be due to EBNA3A/EBNA3C binding
to cis-regulatory elements and is therefore probably a secondary, trans-acting effect of the regu-
lation of an unknown gene(s). However, we cannot rule out binding to extremely long-range
regulatory elements.
Fig 5. Activation of EBNA3A repressesmiR-143/miR-145 expression. (A) MiR-143/miR-145 and RNU48 expression were determined by qPCR in
EBNA3A-ERT2 LCL established without the presence of 4HT (never HT) and 28 days after addition of 4HT to culture medium (+HT). (B) As in (A) but
analysing the expression of ALAS1, CXCL9 and CXCL10 as a controls for activation of EBNA3A following the addition of 4HT.
doi:10.1371/journal.ppat.1005031.g005
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Fig 6. EBNA3A and EBNA3C up-regulate a pri-miR-221/222 of ~28kb. (A) Screen-shot of UCSCGenome Browser at miR-221/miR-222 cluster genomic
locus shows the position of mature miR-221/miR-222 as well as RNA-seq data for GM12878 (LCL), h1-hESC, HeLa-S3, HepG2, HSMM, HUVEC, K562,
NHEK and NHLF cell lines. These RNA-seq data from ENCODE indicate the presence of different sizes of pri-miR-221/222 between cell lines (approximately
2kb, 28kb and 108kb). Red arrows represent the proposed transcription start sites and the asterisk shows the position of primers used. The expression level
of the 28kb pri-miR-221/222 was determined by qRT-PCR in (B) EBNA3A-KO and-REV LCLs as well as in p16-null LCLs 3CHT cultured for 29 days with
(+HT) or without 4HT (Washed); (C) in five EBNA3A-ERT2 LCLs cultured with (+HT) or without 4HT (Washed) for ~30 days; (D) in LCL EBNA3A-ERT2
(never HT) cultured for 28 days with (+HT) or without 4HT; (E) and in p16-null LCL 3CHT (never HT) cultured for 30 days with (+HT) or without 4HT.
doi:10.1371/journal.ppat.1005031.g006
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Fig 7. EBNA3A and EBNA3C bind near the miR-221/miR-222 locus. (A) ChIP-seq data at miR-221/miR-222 cluster genomic locus generated from LCL
3A-TAP and LCL 3C-TAP [27] were displayed using UCSCGenome Browser. EBNA3A and EBNA3C binding sites (BS1, BS2a, BS2b and BS3) are shown
in black squares. The ChIP-seq data from ENCODE for H3K27ac in GM12878 is also displayed. Below it, a schematic representation of the 2kb and 28kb pri-
miR-221/222 is shown. Grey and red arrows show the transcription start site of the 2kb and 28kb pri-miR-221/222 respectively. Positions of primer pairs used
for qPCR to analyse precipitated DNA from ChIP are indicated, along with the positions of previously described enhancers (grey squares A and B) [47]. (B)
ChIP qPCR analyses using anti-Flag antibody to precipitate 3C-TAP and chromatin associated with it in LCL 3C-TAP was performed. As a control for
antibody specificity similar ChIP was performed using LCL infected with B95.8-BAC virus (LCLWT). No binding was detected at the enhancer A (EnhA) used
as negative control. Values represent ratio of chromatin precipitated, after correction for IgG, relative to 2.5% of input. (C) As in (B) but using LCL 3A-TAP in
order to precipitate 3A-TAP protein and associated chromatin. The ENCODE ChIP-seq data indicate a clear peak for RNA Pol II and TBP (https://genome.
ucsc.edu; at coordinates ChrX: 45,629,468–45,629,838 GRCCh37/hg19) this is where the RNA-seq signal for pri-miR-221/222 (28kb) starts, so we have
assumed this was the transcription start site (TSS) throughout our analysis.
doi:10.1371/journal.ppat.1005031.g007
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EBNA3A and EBNA3C increase the level of active chromatin markers
around pri-miR-221/222 TSS
Next, in order to determine whether the up-regulation of pri-miR-221/222 by EBNA3A and
EBNA3C correlates with histone modification and chromatin remodeling, ChIP analyses were
performed on EBNA3A-KO and EBNA3A-REV LCLs as well as EBNA3C-HT LCLs (never
HT) or treated with 4HT (Fig 8). Initially the phosphorylation of the RNA polymerase II at ser-
ine-5 (Ser5)–that indicates transcriptional initiation and activation [77]–was investigated (Fig
8B and 8C). This revealed that the level of phospho-Ser5 Pol II is elevated around the TSS of
28kb pri-miR-221/222 only when both EBNA3A and EBNA3C are expressed and functional
(in EBNA3A-REV and EBNA3C-HT cultured with 4HT). No binding was seen at the putative
2kb TSS. Primers that amplify CXCL10 TSS and ADAM28 TSS were used as controls for
EBNA3A and EBNA3C repressed genes respectively and found, as expected, a higher level of
phospho-Ser5 Pol II only when EBNA3A or EBNA3C were absent/non-functional. We then
performed ChIP analysis for marks of active chromatin (H3K4me3, H3K9ac and H3K27ac)
across the miR-221/miR-222 cluster locus (Fig 8B and 8C). As expected, a higher level of acti-
vation marks was found around the 28kb pri-miR-221/222 TSS only when functional EBNA3A
and EBNA3C were expressed. Again there were no changes around the putative 2kb TSS that
suggest it is regulated. Interestingly, histone activation marks where higher (in particular
H3K9ac and H3K27ac) at BS2a and BS2b sites, that is the region previously described as an
enhancer for miR-221/miR-222, only when both EBV proteins are functional. Taken together
these data are consistent with increased miR-221/miR-222 expression occurring when
EBNA3A and EBNA3C are expressed in an active form, bind chromatin at specific sites and
alter the epigenetic profile of the locus.
EBNA3A and EBNA3C induce expression of the 28kb pri-miR-221/222
by promoting the formation of enhancer-promoter looping
It has recently been shown that the EBNA3 viral proteins can regulate transcription by modu-
lating enhancer-promoter loop formation [20]. So in order to determine whether the EBNA3s
could either promote or disrupt the formation of looping between ‘intragenic’ enhancer ele-
ments (BS2 and BS3 –where both EBNA3A and EBNA3C bind) and the promoter of the 28kb
pri-miR-221/222, chromosome conformation capture (CCC) analysis was performed. A sche-
matic map of the miR-221/miR-222 genomic locus with the location of the HindIII restriction
sites and PCR primers is shown in Fig 9A. The CCC results showed looping interactions
between regions BS2 and BS3 and the promoter, only in EBNA3A-REV LCL and EBNA3C-HT
LCL treated with 4HT (Fig 9B and 9C); that is in cells in which both EBNA3A and EBNA3C
are active and the 28kb pri-miR-221/222 is up-regulated. No looping was found between a con-
trol region (NC) and the promoter for 28kb pri-miR-221/222, but a control PCR product L1/
L2 was found in all samples showing that equal amounts of DNA were present in all reactions
(Fig 9D). These results demonstrate that EBNA3A and EBNA3C are both required for the for-
mation of looping between two sites within an enhancer region and the 28kb pri-miR-221/222
promoter, leading to increased transcription of the pri-miR (Fig 9E).
miR-221/miR-222 inhibition of p57KIP2 expression in LCLs requires
EBNA3A and EBNA3C
MiR-221 and miR-222 have been described as oncogenic miRs (oncomirs) because they are
often expressed at high levels in cancer (see Introduction). Furthermore it has been demon-
strated in various types of non-B cell that they can target mRNAs corresponding to several
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Fig 8. Active chromatin markers and RNA polymerase (Pol) II occupancy on the miR-221/miR-222 cluster genomic locus. (A) ChIP-seq data at miR-
221/miR-222 cluster genomic locus generated from LCL 3A-TAP and LCL 3C-TAP were displayed using UCSCGenome Browser as in Fig 7A. A schematic
representation of the 2kb and 28kb pri-miR-221/222 is shown with grey and red arrows representing each transcription start site (TSS). Positions of primer
pairs used for qPCR to analyse precipitated DNA from ChIP are indicated along with the position of previously described enhancers (grey squares A and B)
[47]. (B) ChIP was performed on extracts from EBNA3A-KO and EBNA3A-REV LCL (D3) and antibodies specific for phospho-Ser5 Pol II, H3K4me3,
H3K9Ac and H3K27Ac were used. As a control for antibodies and cell lines, a primer pair for CXCL10 TSS was used. Values represent ratio of chromatin
precipitated, after correction for IgG, relative to 2.5% of input. (C) As in (B) but using p16-null LCL 3CHT (LCL 3CHT never HT) cultured for 30 days with (LCL
3CHT +HT) or without 4HT. For the ChIP using LCL 3CHT, ADAM28 TSS primer pair was used as control.
doi:10.1371/journal.ppat.1005031.g008
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Fig 9. EBNA3A and EBNA3C induce chromosome looping at the miR-221/miR-222 cluster locus. (A) Schematic of the miR-221/miR-222 cluster locus
depicts the location of both miRs, the HindIII sites, the 28kb pri-miR-221/222 transcription start site and primers used for the chromosome conformation
capture assay. (B) EBNA3A-KO and EBNA3A-Rev LCLs (D3) were used for chromosome conformation analysis. Interaction between the promoter (P) of the
28kb pri-miR-221/222 and EBNA3A/3C binding site 2 (BS2 –including BS2a and BS2b, see Fig 8A) or 3 (BS3) is dependent on the presence of EBNA3A.
PCR primers (NC) corresponding to a site located downstream of the miR-221/miR-222 locus were used as a negative control. Positive control (+ve control)
showed PCR reactions using a DNA control template. (C) Same as (B) but using p16-null LCL 3CHT (LCL 3CHT never HT) cultured for 30 days with (LCL
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tumour suppressor genes and promote their translational inhibition and/or degradation. There
are multiple reports that the CDKIs p57KIP2 and p27KIP1 are targets and a single report of the
pro-apoptotic p53-response protein PUMA in epithelial cells [50,56,57,58,59,76].
We first determined whether p57KIP2 and p27KIP1 were miR-221/miR-222 targets in LCLs.
To do this EBNA3A-REV cells were electroporated with LNA anti-miR-221, anti-miR-222,
both anti-miRs, or a negative control. The electroporation of anti-miR-221, anti-miR-222 or
both was accompanied by an increase in p57KIP2 protein level, and p27KIP1 increased only
when miR-221 was inhibited (Fig 10). For comparison we also analysed expression of the
related CDKI, p21CIP1 (not known to be a miR-221/miR-222 target) and found no change
when the miRs were inhibited. The level of PUMA was also unaltered in this B cell context.
These depletion experiments relied upon poor transfection efficiencies common to all LCLs,
therefore in most cells of the population the specific miRs were not inactivated. Nevertheless
taken together, the data established to our satisfaction that p57KIP2 and (to a lesser extent)
p27KIP1 are targets of the miR-221/miR-222 cluster in EBV-transformed human B cells.
The expression of p57KIP2 was therefore subjected to more detailed and stringent analyses.
The results, (compiled in Fig 11), unambiguously demonstrated across multiple LCLs carrying
either EBNA3A-KO or-revertant EBV, or LCLs conditional for EBNA3A or EBNA3C, that
p57KIP2 protein expression is almost completely ablated when EBNA3A and EBNA3C are both
active. However, if either of these EBNA proteins is absent or inactivated, substantial amounts
of p57KIP2 can be detected. Analysis by qPCR also showed significant increases of mRNA cor-
responding to p57KIP2 in the absence of functional EBNA3A or EBNA3C, but the degree of reg-
ulation was rather more variable between cell lines than was the protein expression (Fig 11).
These results suggest that miR-221 and miR-222 not only block translation, but might also
enhance the degradation of p57KIP2 mRNA (both mechanisms of action have been described
[33,34].
MiR-221 and miR-222 have also been reported to regulate p27KIP1 in non-B cells. In our
miR inhibition assay (Fig 10) we showed that p27KIP1 increased after miR-221 inhibition but
not miR-222. Although we see regulation of p27KIP1 protein levels by EBNA3A in LCLs, it is
neither as robust nor quite as consistent as the regulation of p57KIP2 (for examples see S10 Fig)
—currently we do not know the reasons why p27KIP1 and p57KIP2 are differentially regulated in
these lines.
Induction of p57KIP2 coincides with reduced phosphorylation of the Rb
protein and cell proliferation in EBNA3A-ERT2 cells minus 4HT
In order to determine the consequences of up-regulating p57KIP2 in LCL cells that have grown
out after infection of normal primary B cells with the minimum of selection, an early passage
(<2 months post-infection) EBNA3A-ERT2 line produced from a mixed donor population of
B cells (LCL 5) was used. This line was established in the presence of 4HT and the cells express
little or no p57KIP2, but on removal of 4HT from the culture medium, they soon produce sub-
stantial amounts of p57KIP2 protein (Figs 11B and 12A). Consistent with the increase in
p57KIP2 there was a pronounced reduction in the phosphorylation of the tumour suppressor
Rb and this was associated with a gradual reduction in proliferation as revealed by reduced
DNA synthesis (EdU incorporation) and reduced cell population growth (Fig 12). Similar anal-
ysis was repeated on several other independent EBNA3A-conditional LCLs and produced
3CHT +HT) or without 4HT. Interaction between P to BS2 and P to BS3 occurred only when EBNA3C is active (LCL 3CHT +HT). (D). Loading control primers
L1 and L2 amplify DNA contained in a single HindIII fragment and have been used as DNA loading control between the DNA samples used for chromosome
conformation capture. (E) Schematic model of chromatin loop formation induced by EBNA3A and EBNA3C at miR-221/miR-222 cluster locus.
doi:10.1371/journal.ppat.1005031.g009
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essentially identical results (S11 Fig). An important enzyme necessary for the phosphorylation
of Rb is the cyclin-dependent kinase CDK6. Therefore the most likely explanation for the inhi-
bition of Rb phosphorylation is the binding of p57KIP2 to CDK6 resulting in inactivation of the
latter (see co-immunoprecipitations in S12 Fig). The effect of low levels of miR-221/miR-222
and high levels of p57KIP2 on the proliferation of these cells was surprisingly modest, rather less
than has been reported previously in EBNA3A-conditional LCLs when EBNA3A was inacti-
vated [10,78]; we do not know the reason for this, but as we have indicated above, different
lines can have different properties because of clonal variation. The roles and interactions of the
various CDKIs regulated by EBV are discussed in more detail below.
Discussion
Using a reverse genetics approach, made possible by the use of LCLs carrying knockout, rever-
tant or conditional-EBV recombinants, we have explored the roles of the EBNA3 proteins in
Fig 10. Inactivation of miR-221 andmiR-222 in LCLs with corresponding anti-miRs. LCLs were
electroporated with the anti-miR indicated; p57KIP2, p27KIP1 p21CIP1 and PUMA expression have been
analysed by western blot. The blot was probed for γ-tubulin as an additional control for loading and a non-
targeted protein. There were increases in 57KIP2 and p27KIP1, but not p21CIP1 or PUMA in cells transfected
with the specific LNA anti-miRs.
doi:10.1371/journal.ppat.1005031.g010
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the regulation of cell miRs in B cells. This has revealed that both EBNA3A and EBNA3C –but
not EBNA3B –are required for the transactivation of the oncomiRs miR-221 and miR-222,
while concurrently silencing the expression of the tumour suppressor miR-143/miR-145
cluster.
Both EBNA3A and EBNA3C were shown by ChIP experiments to associate with multiple
sites in a genomic region about 19kb upstream of the miR-221/miR-222 coding sequences
Fig 11. EBNA3A and EBNA3C regulate p57KIP2 expression. (A) Western blot showing the level of p57KIP2 expression in four EBNA3A-KO (KO) LCLs and
their revertant equivalent (REV) (used in Fig 1). Below eachWestern blot is shown the level of p57KIP2 mRNA determined by qPCR, normalized to GN2BL1
and relative to each “wild type” cell LCL EBNA3A-REV (3A-REV) of which the mRNA level is set to 1. (B) As in (A) but using five EBNA3A-ERT2 conditional
LCLs cultured with (+) or without (-) 4HT (used in Fig 4). (C) Western blot showing the expression of p57KIP2 protein (left panel) and qPCR showing the level
of p57KIP2 mRNA (right panel) in two p16-null LCL 3CHT cultured with (+) or without (-) 4HT (used in Fig 1).
doi:10.1371/journal.ppat.1005031.g011
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and about 9kb downstream from the pri-miR TSS that is dominant in LCLs. These EBNA3
binding sites correspond to a region previously identified functionally and by histone modifi-
cations as an enhancer of transcription. So the data are consistent with the miRs being directly
transactivated by the combined action of EBNA3A and EBNA3C. This cooperation between
these two EBNA3 proteins to modulate transcription is reminiscent of the regulation of many
host protein-encoding genes in EBV-infected LCLs [14,20,28,29]. At this stage it is not possi-
ble to say what factors are responsible for recruiting EBNA3A and or EBNA3C to BS2a, BS2b
Fig 12. The increase of p57KIP2 level is associated with de-phosphorylation of Rb and reduced entry into S phase and proliferation. (A) Western blot
analysis of extracts from LCL EBNA3A-ERT2 (line 5) cultured with (+) or without (-) 4HT for 30 days showing that after inactivation (and degradation) of the
EBNA3A-ERT2 fusion protein, p57KIP2 expression increases, and the amount of hyperphosphorylated Rb (ppRb) is dramatically reduced and is no longer
detected using a phospho-Rb-specific antibody. The blot was probed for γ-tubulin as a control for loading. (B) Cell cycle distribution of LCL EBNA3A-ERT2
(line 5) culture with or without 4HT for four weeks was determined by flow cytometry following exposure to EdU for 2 hours (2h pulse). (C) A comparison of the
population growth rate between these cells cultured with or without 4HT was analysed by counting the number of viable cells every 2–3 days. Total cell
numbers were plotted at each time point. Data are representative of two independent experiments.
doi:10.1371/journal.ppat.1005031.g012
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and BS3, nevertheless ENCODE data indicate >20 transcription factors that could bind at
these sites in the GM12878 LCL (S13 Fig). This list includes many factors previously reported
to be involved in the recruitment of EBNAs to sites across the human genome (eg ATF2,
BATF, PAX5, RUNX3 and SPI1 [19,20,29]).
Since EBNA3A and EBNA3C were found to bind to multiple sites in a previously character-
ised enhancer element—we assumed, and then confirmed, that transactivation involves modu-
lation of the local three-dimensional architecture of chromatin (long-range ‘looping’) that
brings the enhancer elements into contact with the TSS of the 28kb pri-miR only when func-
tional EBNA3A and EBNA3C are present (see Fig 9). Similar topological changes have been
reported in the regulation of protein encoding genes such as the ADAM28/ADAMDEC1 locus
[20,21]. However, at most of the EBNA3A/EBNA3C regulated genes that have been well char-
acterised [for example BIM (BCL2L11), p16INK4a (CDKN2A) and the ADAM28/ADAMDEC1
locus] transcription is repressed; and this is probably because these two viral proteins can
recruit cellular co-repressors such as HDACs, CtBP and components of polycomb protein
complexes (see Introduction). On some genes they can also displace the EBV transactivator
EBNA2, resulting in substantially reduced transcription [20,21]. Here, for the first time, we
describe a long-range enhancer—promoter interaction mediated by EBNA3A and EBNA3C
resulting in increased transcription, ie activation. But very little is known about how EBNA3A
and EBNA3C together might activate transcription, although it is probably related to the their
capacity to physically interact with each other [27] and perhaps recruit co-activators such as
the histone acetyltransferase p300 [22]. This mechanism would be consistent with the increase
in acetylation seen on histone H3 lysine-27 (H3K27ac) at the enhancer binding sites and
around the promoter when the miR-221/miR-222 locus is activated (Figs 7A and 8). The con-
sensus of opinion is that in this type of gene regulation—that involves chromatin looping—cel-
lular repressors or activators are recruited in a context-specific manner, but what cofactors,
features of genomic sequence and chromatin topology determine whether the outcome is
repression or activation, remain largely unknown (reviewed in [79]).
It has been previously reported that EBV can induce expression of miR-221/miR-222
[80,81] and that the latency-associated protein LMP1 can activate miR-221/miR-222 expres-
sion after single gene transfer into BL-derived cells [82]. Moreover, the cluster can also be acti-
vated by NF-kB [47]. Since LMP1 is expressed in all the LCLs used in this study (see for
example Fig 3) and activates NF-kB signaling, we cannot rule out the possibility that signal
transduction from this viral membrane protein also contributes to the activation of the 28kb
pri-miR. It is possible that EBNA3A and EBNA3C acting together play a role in reorganizing
local chromatin in order to potentiate LMP1 and NF-kB-mediated transactivation of miR-221/
miR-222.
Silencing of the miR-143/miR-145 locus by the combined action of EBNA3A and
EBNA3C remains poorly understood. Since no EBNA3 binding sites were detected within
more than a million DNA base pairs either side of the pri-miR-143/145 TSS (S9 Fig), it is
likely that this repression of transcription is a secondary, downstream event triggered by
altered expression of another EBNA3A/EBNA3C-target gene. However, we are currently
unable to formally test this.
The two miR clusters described here are deregulated in multiple human cancers, including
B cell lymphomas (see Introduction) and therefore probably have the potential to influence B
cell proliferation, transformation, and EBV-associated lymphomagenesis. The details of how
the tumour suppressors miR-143 and miR-145 might inhibit cell proliferation are poorly
understood. They co-operatively promote differentiation and repress proliferation in several
cancer and primary cell lines and are both up-regulated during senescence in human fibro-
blasts [60,61,62]. It may be significant that miR-143 and miR-145 are also repressed by the E7
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oncoprotein in epithelial cells infected with human papillomavirus (HPV)-31 [83]. Although
various target mRNAs have been proposed, there appears to be a lot of cell-type specificity and
a general lack of consensus on precisely how miR-143/miR-145 act as tumour suppressors.
There are very few data available on the activities of miR-143/miR-145 in B cells, although
there has been one report of their down-regulation in EBV-transformed, but not in mitogen-
stimulated B cells [84].
In contrast to miR-143/miR-145, functions of the miR-221/miR-222 cluster is relatively
well characterised, with wide agreement that two of the major targets are mRNAs for CIP/KIP
CDKIs p57KIP2 and p27KIP1, the translation of which are robustly inhibited by these miRs in
various types of cell (see Introduction). We, and others, had previously shown that EBNA3A
and EBNA3C can block transcription of two members of the INK4 CDKI family, p16INK4a
and p15INK4b [12,30,32,78]. Furthermore it has been reported that these same two EBV pro-
teins might also repress expression of a third member of the CIP/KIP family, p21CIP1 [85,86].
Since intrinsic cell cycle inhibitors are emerging as important targets of EBNA3A and
EBNA3C, we focused on the consequences of miR-221/miR-222 induction in LCLs. Utilizing
multiple cell lines carrying either knockout mutant viruses or viruses conditional for
EBNA3A or EBNA3C expression, we have clearly established that in B cells, transformed by
and latently infected with EBV, both EBNA3A and EBNA3C are necessary to inhibit expres-
sion of p57KIP2 and (less robustly and reproducibly) p27KIP1. Both of these proteins can act as
tumour suppressors by reducing cell proliferation because they target and inhibit CDKs 2,4,6
(see schematic in Fig 13; reviewed in [87]). Reducing the expression of these CIP/KIP CDKIs
via miR-mediated inhibition is therefore likely to enhance the proliferation of LCLs and might
play a role in establishing EBV persistence in B cells in vivo. It could also contribute to the
development of EBV-associated B cell lymphomas such as those in the immunocompromised,
in DLBCL [52,53,54] and in the sub-group of BL that express the EBNA3s (known as Wp-
restricted BL [88]).
It should also be noted that in many of the LCLs used in this study—particularly those pas-
saged for prolonged periods—induction of p57KIP2 had little or no effect on proliferation. We
suspect in some cases this is because genetic or epigenetic impairment of the Rb tumour sup-
pressor hub is readily selected in the expansion of these rapidly proliferating cell populations
(see Introduction). Alternatively, p57KIP2 may not always have a significant anti-proliferative
effect in activated B cells and may sometimes produce more subtle phenotypes. It is important
to remember that EBNA3A and EBNA3C together repress multiple cell cycle inhibitory path-
ways that culminate in the inactivation—by phosphorylation—of the tumour suppressor pro-
tein Rb (Fig 13); that is, there appears to be considerable redundancy. The currently available
data suggest that p16INK4a is the major CDKI to be targeted in B cell transformation [30,31],
but it now appears that p15INK4b, p57KIP2, p27KIP1 and p21CIP1 might all have to be controlled
in the molecular balance required for the establishment of EBV latency. It will require painstak-
ing analysis using EBV with specific mutations in EBNA3A and EBNA3C and shRNA and/or
gene-editing technologies to dissect and resolve these effects on B cell proliferation, senescence
and perhaps differentiation.
In summary, it appears that during the co-evolution of EBV and its host, two cooperating
factors (EBNA3A and EBNA3C) have emerged to control transcription of not only host cell
genes, but also long non-coding pri-miRs and miRs. It is remarkable that two distinct families
of cell cycle inhibitory factors—the INK4 and CIP/KIP CDKIs—are a specific focus in this dou-
ble-routed regulation of the host proteome. The implication is that extending the proliferation
of B cells via the activities of EBNA3A and EBNA3C is a very important feature of EBV biology
in vitro and therefore in vivo.
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Materials and Methods
MicroRNA profiling by TaqMan quantitative real-time PCR low density
array (TLDA)
RNA was isolated usingmirVana miRNA isolation Kit (Ambion) including the optional step
for enrichment of small RNA (<200bp), which enables more sensitive detection of low-level
small RNAs. Taqman MicroRNA RT kit and Megaplex Primer Pool A (ABI) were used to
reverse transcribe up to 381 microRNAs in a single reaction according to the manufacturer’s
instructions. Generally 300ng of RNA was reverse transcribed per reaction and the cDNA
product was used in qPCR without pre-amplification.
Three hundred and seventy seven human microRNAs were profiled by real-time qPCR
using the Taqman MicroRNA A Card v 2.0 (ABI). cDNA was diluted, mixed with Taqman
Fig 13. EBNA3A and EBNA3C together modulate the activity of multiple cell cycle inhibitors bymore
than onemechanism. Schematic representation of how, by acting together, EBNA3A and EBNA3C regulate
members of two families of cyclin-dependent kinase inhibitors (CDKIs). EBNA3A and EBNA3C jointly repress
expression of the two closely related INK4 CDKIs p16INK4a (encoded by CDKN2A) and p15INK4b (encoded by
CDKN2B). In both cases repression of transcription is associated with the tethering of EBNA3A and EBNA3C
to chromatin in the region of the CDKN2A/CDKN2B locus [19,30,32]. Inhibition of transcription involves the
polycomb-mediated epigenetic histone modification H3K27me3. In this report the same combination of
EBNA3 proteins has been shown to repress two members of the second (CIP/KIP) family of CDKIs. Here
repression of protein expression is not directed at the transcription of the genes for p57KIP2 (CDKN1C) and
p27KIP1 (CDKN1B), but is post-transcriptional and mediated by the miR-221/miR-222 cluster that is directly
transactivated by EBNA3A and EBNA3C. The biochemically related proteins p16INK4a and p15INK4b both
have the capacity to inhibit CDK4 and CDK6 activity. The CIP/KIP kinases are more promiscuous and target,
in addition, other CDKs including CDK2. Recently there have been reports that EBNA3A and EBNA3C can
each also regulate the third member of the CIP/KIP family, namely p21CIP1 [85,86] but the mechanisms in
LCLs have not been clearly defined.
doi:10.1371/journal.ppat.1005031.g013
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Universal PCR Master Mix II (ABI) and loaded into the pre-configured micro-fluidic card.
Real-time reaction was run on a 7900HT Real-Time PCR System (ABI) and data analyzed
using the SDS RQ manager software (ABI).
Construction of recombinant EBV-BAC EBNA3A-ERT2
An EBNA3A-ERT2 fusion protein (3A-ERT2) was constructed in the B95-8 EBV background
using the 4-hydroxytamoxifen-sensitive human estrogen receptor ERT2 containing the
G400V/M543A/L544A triple mutation [89]. The connection between EBNA3A and ERT2 is a
small linking sequence of 9 amino acids (GTGGVGQD) between the last amino acid of
EBNA3A and amino acid 281 of ERT2. This fusion was recombined into the B95-8 bacterial
artificial chromosome (BAC) using previously described methods [12,90,91] to produce BAC
containing 3A-ERT2.
Cell culture
Established LCLs were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10%
fetal calf serum, penicillin and streptomycin. LCL 3A-ERT2 and 3CHT were cultured with addi-
tion of 400nM of 4-hydroxytamoxifen (4HT, Sigma) where stated. After the infection of primary
B cells, LCLs were grown to a volume and density suitable for freezing multiple aliquots (typi-
cally about 60ml at a density of 3×105 cells/ml or greater). This took 4–6 weeks for 3A-ERT2,
3CHT, revertant LCLs and 6–12 weeks for the 3A-ERT2 grown without 4HT and EBNA3A
mutant LCLs. LCLs 3CHT established in a p16-null background are described in [30]. Cells
recovered from liquid nitrogen were cultured for at least 10 days (with 4HT if necessary) before
the start of any experiment. At the end of an experiment the cells were discarded. Twenty-four
hours before any experimental treatment, cells were seeded at a density of 3×105 cells/ml.
Infection of 1°B cells with recombinant EBV
Recombinant viruses were constructed and produced as described previously [12,91]. Primary
B cells for the generation of LCL 3A-ERT2 and EBNA3-knockout and revertant LCLs were iso-
lated from anonymous buffy coat residues (UK Blood Transfusion Service) by centrifugation
over Ficoll. EBNA3A-knockout and revertant LCLs were made by infection of CD19+ B cells
from four independent donors (D1, D2, D3, D4). LCL 3A-ERT2 line 5 was made by infection
of CD19+ B cells from mixed donors. D11 (lines 1 and 2) and D13 (lines 3 and 4) 3A-ERT2
LCLs were made by infection of PBLs isolated from donors D11 and D13 with EBNA3A-ERT2
virus. To produce all LCLs, between 50μl and 1ml of virus was added to 106 PBLs or 3×106
CD19+ purified B cells in a well of a 24 well plate, and cultured initially in RPMI, supplemented
with 15% FCS and with Cyclosporine A (500 ng/ml) for the first 2 weeks. Once LCLs had
grown out into large culture volumes, the FCS level in the medium was reduced to 10%.
Flow cytometry
Cell proliferation analyses were performed as described previously [30] by measuring the
incorporation into DNA of nucleotide analogue EdU during a 2h pulse (Life Technologies).
Cell fluorescence was measured on LSR II (Becton Dickinson) flow cytometer. Single cells were
gated based on FxCycle Far Red fluorescence—Life Technologies (comparing fluorescence area
to width or height at 633/690). The LIVE/DEAD Fixable Violet stain (Life Technologies) was
used to determine the viability of cells (Fluorescence measured by 405/450 filters indicated
live/dead status), and only live cells were included for the assessment of proliferation by EdU
(488/530).
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Western immunoblotting
SDS polyacrylamide gel electrophoresis and Western blotting was performed essentially as
described previously [12,27,91]. In some cases the membrane used for Western blotting was
cut horizontally after protein transfer in order to facilitate multiple antibody probes and a sin-
gle loading control for each blot.
Co-immunoprecipitation assays
LCLs were harvested and lysed in immunoprecipitation (IP) buffer (50mM Tris-HCl pH 7.5,
150mMNaCl, 1mM DTT and 0.5% Nonidet P-40) plus protease inhibitors (Roche Molecular
Biochemicals). Protein concentration was estimated colorimetrically using the Bio-Rad deter-
gent-compatible assay and 250μg were used per IP. Cell extracts were then pre-cleared with
30μl of Protein G-Sepharose beads (GE Healthcare) at 4°C for 1h. Complexes were precipitated
with specific antibodies (S1 Table) and the mixture was incubated at 4°C overnight. Then, 30μl
of protein G-Sepharose beads were added for 1h at 4°C, washed four times in IP buffer and the
immunopurified proteins were resolved by SDS-PAGE and detected by western blot.
MicroRNA, mRNA and quantitative real time PCR (qPCR)
For qPCR, total RNA (including microRNA) was extracted from approximately 5×106 cells for
each cell line using the miRNeasy mini kit from Qiagen and following the manufacturer's
instructions. Expression of miR-221, miR-222, miR-143, miR-145 and two snRNAs, RNU6B
and RNU48 were quantified by qPCR using the TaqMan MicroRNA Assay listed in S2 Table
(Applied Biosystem). Briefly, cDNA was synthesised from 10ng of total RNA using Taqman
miRNA primers and the TaqMan MicroRNA Reverse Transcription Kit. qPCR was then per-
formed using the TaqMan Universal PCR Master Mix. The cycling conditions were 95°C for
10min, followed by 45 cycles of 15sec at 95°C and 60sec at 60°C.
For mRNA analysis, one microgram of each RNA sample was reverse-transcribed using
SuperScript III First-Strand Synthesis Supermix for qPCR (Invitrogen). 10 ng of cDNA product
was then used per qPCR reaction (except for the detection of pri-miR-143/145 where 100ng
were used) using Platinum Sybr Green qPCR SuperMix UDG kit (Invitrogen). Dissociation
curve analysis was performed during each run to confirm absence of non-specific products.
Sequences of the primers used are listed in S3 Table.
All qPCR were performed on an ABI 7900HT real-time PCR machine. GNB2L1 and
RNU6B were used as endogenous controls for mRNA and miR respectively. Relative mRNA
or miR expression was calculated using the comparative Ct (ΔΔCT) method. The calculated
errors in the graphs are the standard errors from three replicate qPCR reactions for each
mRNA or miR.
Chromatin immunoprecipitations (ChIP)
ChIP assay and qPCR analysis were performed essentially as described previously [27]. Anti-
bodies and sequences of the primers used in these assays are listed in S1 and S4 Tables
respectively.
Chromosome conformation capture assay
Chromosome conformation capture assay was performed as previously described [92,93] with
minor modification. Briefly, ten millions LCL were filtered through a 70μm cell strainer to
obtain a single-cell preparation and fixed in 1% formaldehyde for 30 minutes at room tempera-
ture. The fixation reaction was stopped by quenching with 0.125M glycine, cells were washed
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twice with cold PBS containing protease inhibitors, re-suspended in 500μL of lysis buffer and
lysed for 10 minutes on ice. Nuclei were collected and digested with 400 units of HindIII
(20,000 U/mL, New England Biolabs) overnight at 37°C. The restriction digest reaction was
stopped by addition of SDS (1.6% final concentration) and incubation at 65° for 30 minutes.
The intramolecular ligation was performed by adding 100 Weiss units of T4 DNA ligase to the
10-fold diluted sample for 4h at 16°C followed by a 45 minutes incubation at room tempera-
ture. Protein digestion and reverse cross-linking was performed with overnight incubation at
65°C with 300μg proteinase K. RNA was then degraded with 300μg RNase for 1h at 37°C.
Finally the DNA was twice phenol/chloroform extracted and ethanol-precipitated. Purified
DNA was analysed by conventional PCR.
The generation of control template for ligation products was performed as previously
described [20]. In brief, DNA regions covering the restriction sites of interest were PCR ampli-
fied, purified, mixed in equimolar amount and subjected to digestion with HindIII for 2 hours.
The digested PCR products were ligated with 10 Weiss unit of T4 DNA ligase overnight at
16°C, purified and analysed by conventional PCR.
Locked nucleic acid (LNA) knockdown of miR-221 and miR-222
LCLs 3A-REV were electroporated with 50 nM of LNA anti-miR-221 oligonucleotide (hsa-
miR-221 miRCURY LNA, Exiqon), LNA anti-miR-222 oligonucleotide (hsa-miR-222 miR-
CURY LNA, Exiqon) or scrambled oligonucleotide (miRCURY LNAmicroRNA inhibitor con-
trol, Exiqon) using a Bio-Rad Gene Pulser I (270V, 960μF). After 48 h, dead cells and debris
were removed by layering the cells over 3ml Ficoll-plaque (GE Healthcare). Live cells were
then collected washed in PBS and extraction was performed as previously described for West-
ern blotting.
Ethics statement
The primary human B cells used in this study were isolated from buffy-coat residues purchased
from the UK Blood Transfusion Service; these were derived from the blood of anonymous vol-
unteer blood donors. No ethical approval is required.
Supporting Information
S1 Table. List of antibodies.
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S2 Table. Taqman MicroRNA assays.
(DOCX)
S3 Table. Gene expression qRT-PCR primer sequences.
(DOCX)
S4 Table. ChIP qPCR primer sequences.
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S5 Table. Chromosome conformation capture primer sequences.
(DOCX)
S1 Fig. Western blot analysis of the EBNA3 proteins in LCLs used in this study. (A) West-
ern blot analysis of EBNA3A expression from four independent LCLs EBNA3A-KO and
EBNA3A-REV (D1, D2, D3 and D4). (B) Expression of EBNA3C-HT was evaluated by west-
ern blot analysis from two p16-null LCL 3CHT (A2 and C1) cultured for 29 days with (+) or
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without 4HT (-). (C) Western blot analysis of EBNA3C-HT expression from p16-null LCL
3CHT established without the presence of 4HT (never HT) or 30 days after 4HT (+HT) was
added to culture medium. (D) EBNA3B expression in LCL D1, D2, D3 and D4 EBNA3B-KO
(3B-KO) and EBNA3B-REV (3B-REV) was evaluated by Western blot. (E) EBNA3A-ERT2
expression from EBNA3A-ERT2 LCLs established without the presence of 4HT (never HT)
and 28 days after addition of 4HT (+HT) to culture medium evaluated by Western blotting. All
blots were probed for γ-tubulin as a control for loading.
(TIF)
S2 Fig. Expression of miR-143/miR-145, miR-221/miR-222 and control RNA RNU48 are
not affected by the treatment of LCLWT by 4HT.MiR expression, as well as control RNU48,
was determined by qPCR using RNA extracted from two independent wild type (B95-8-BAC)
LCLs, established from two different donors (D11 and 13), after being treated or not with HT
for 30 days.
(TIF)
S3 Fig. Control RNAs RNU48 and ALAS1 were unaffected by EBNA3A or EBNA3C
whereas CXCL9/10 and ADAM28/ADAMDEC1 are repressed by EBNA3A and EBNA3C
respectively. (A) RNU48 and ALAS1 expression from LCL D1, D2, D3 and D4 EBNA3A-KO
and EBNA3A-REV as well as from p16-null LCL 3CHT A2 and C1 cultured for 29 days with
(+HT) or without 4HT (Washed). Expression was determined by quantitative PCR (qPCR).
(B) Expression of the EBNA3A-repressed genes CXCL9 and CXCL10 were assessed by qPCR
on the EBNA3A-KO and EBNA3A-REV (D1, D2, D3 and D4) cell lines as a control for the
presence/absence of functional EBNA3A (C) Expression of EBNA3C-repressed genes
ADAM28 and ADAMDEC1 were also determined by qPCR on the EBNA3C-conditional
(p16-null cell lines) cultured with (+HT) or without 4HT (Washed) as a control for the func-
tional EBNA3C.
(TIF)
S4 Fig. Comparison of miR-221 and miR-222 level across several independent LCLs. Levels
of miR-221 and miR-222 were compared between LCL D1, D2, D3, D4 EBNA3A-KO and-
REV, p16-null 3CHT A2 and C1 culture with (+HT) or without HT (Washed), LCL D1, D2,
D3, D4 EBNA3B-KO and-REV. MiR expression was normalized to RNU6B and is shown rela-
tive to LCL D1 EBNA3A-REV.
(TIF)
S5 Fig. EBNA3A represses CXCL9 and CXCL10 in LCL EBNA3A-ERT2. Expression levels of
the well characterised EBNA3A repressed genes CXCL9 and CXCL10 were also determined as
a control for the inactivation of EBN3A when 4HT was removed from the culture. Expression
of control RNAs ALAS1 and RNU48 expression were also determined.
(TIF)
S6 Fig. EBNA3A and EBNA3C both up-regulate miR-221 and miR-222 expression after
their activation in the conditional LCLs.MiR-221 and miR-222 expression were determined
by real time quantitative RT-PCR (qPCR) from EBNA3A-ERT2 LCLs established without the
presence of 4HT (never HT) and 28 days after addition of 4HT to culture medium (+HT) and
from p16-null LCL 3CHT also established without the presence of 4HT (never HT) or 30 days
after 4HT (+HT) was added to culture medium.
(TIF)
S7 Fig. EBNA3A and EBNA3C both repress the pri-miR transcript for miR-143/miR-
145. The expression level of the non-coding RNA precursor of miR-143/miR-145 was
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determined (A) in EBNA3A-KO and-REV LCLs; (B) in EBNA3A-ERT2 LCLs cultured with
(+HT) or without 4HT (Washed); (C) in p16-null LCLs 3CHT with (+HT) or without 4HT
(Washed); (D) in LCL EBNA3A-ERT2 (never HT) cultured for 28 days with (+HT) or with-
out 4HT; (E) and p16-null LCL 3CHT (never HT) and cultured for 30 days with (+HT) or
without 4HT.
(TIF)
S8 Fig. Validation of LCLWT, LCL 3A-TAP, LCL 3C-TAP used for ChIP. (A) EBNA3A-
TAP, EBNA3B and EBNA3C-TAP expression in the cell lines LCLWT, LCL 3A-TAP, LCL
3C-TAP used in ChIP experiment was evaluated by Western blot. The blot was probed for γ-
tubulin as a control for loading. (B). ChIP analysis using an anti-Flag antibody was performed
as in Fig 7. Primers for the Myoglobin promoter (Myo) were used for qPCR as negative control,
whereas primers for known EBNA3A/3C binding sites at the ADAM28/ADAMDEC1 inter-
genic enhancer (ADAM) and CtBP2 locus (CTBP2) were used as positive controls of EBNA3
binding. Values represent ratio of chromatin precipitated, after correction for IgG, relative to
2.5% of input.
(TIF)
S9 Fig. EBNA3A and EBNA3C do not bind within at least 1Mbp either side of the putative
TSS of the pri-miR-143/145. ChIP-seq data at the miR-143/miR-145 cluster genomic locus
generated from LCL 3A-TAP and LCL 3C-TAP (Paschos et al., manuscript in preparation)
were displayed using UCSC Genome Browser. The non-coding pri-miR-143/145 (called
MIR143-HG in the genome browser) as well as miR-143/miR-145 are highlighted by inclusion
in a red box.
(TIF)
S10 Fig. Expression of the CDKI p27KIP1 in LCLs. (A) Western blot showing the expression
level of p27KIP1 from four EBNA3A-KO (KO) LCLs and their revertant equivalents (REV).
Below the Western blot is the p27KIP1 mRNA expression level. (B) As in (A), but from five
LCLs EBNA3A-ERT2 conditional cell lines cultured with (+) or without (-) 4HT for ~30 days.
(C) Western blot showing the expression of p27KIP1 protein and qPCR showing the mRNA
level corresponding to p27KIP1 from two (p16-null) LCL 3CHT cultured with (+) or without (-)
4HT. All the blots were probed for γ-tubulin as a control for loading.
(TIF)
S11 Fig. The effect of removing of 4HT from different 3A-ERT2 LCLs on pRb phosphoryla-
tion and population growth. (A) Western blot showing the expression of hyperphosphory-
lated Rb (ppRb). γ-tubulin was used as a control for loading. (B) A comparison of the
population growth rate between four 3A-ERT2 LCLs (line 1–2 being established from donor
D11 and line 3–4 donor D13) cultured with (+HT) or without (Washed) 4HT for ~2 months
was analysed by counting the number of viable cells every 2–3 days. Total cell numbers were
plotted at each time point. As control, two wild-type LCLs from the same background as
3A-ERT2 LCLs (D11 and D13) were treated or not with HT. Data are representative of at least
two independent experiments.
(TIF)
S12 Fig. p57KIP2 co-immunoprecipitates with CDK6. Immunoprecipitation was performed
with mouse anti-CDK2 or anti-CDK6 antibodies on extracts from LCL D4 EBNA3A-REV and
EBNA3A-KO. A large excess of mouse IgG was used as a control for non-specific binding and
precipitates were compared to 10% input after Western blots were probed for p57KIP2, CDK2
or CDK6. p57KIP2 (arrowed) appears to precipitate with CDK6 but not CDK2.
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Immunoglobulin chains are indicated and the asterisk indicates an unidentified non-specific
protein band.
(TIF)
S13 Fig. EBNA3A and EBNA3C binding sites on miR-221/miR-222 locus can also bind
multiple transcription factors. ENCODE GM12878 ChIP-seq data at the EBNA3A and
EBNA3C binding sites BS1, BS2 (BS2a and BS2b) and BS3 showed multiple transcription fac-
tors also bind to those regions (displayed using UCSC Genome Browser). The three EBNA3s
binding sites are highlighted by inclusion in a red box.
(TIF)
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